

Evaluation of QTc and Tp-e Changes in Rheumatoid Arthritis and Ankylosing Spondylitis Patients Treated with Biological Drugs

Mir Amir Aghdashi¹ , Mojgan Hajahmadi Pourrafsanjani ^{*2} , Tayebe Mokari³ 

¹ Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Email: maaghdashi@umsu.ac.ir

² Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. hajahmadimojgan@gmail.com

³ Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Email: Mokari.t@gmail.com

Corresponding Author, Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. hajahmadimojgan@gmail.com

Article Info

Article type:

Original Article

Article History:

Received: 21 Jan 2023

Received in revised form:
07 March 2023

Accepted: 20 December
2023

Published online: 31
December 2023

Keywords:

Electrocardiogram,
Rheumatoid arthritis,
Ankylosing Spondylitis,
Biological drugs

Abstract

Objective: Tumor necrosis factor- α (TNF- α) antagonists bring about significant improvement in chronic inflammatory diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SpA), but they may have negative myocardial effects. This study aimed to evaluate the changes in QT corrected (QTc) and T-peak to T-end (TpTe) in RA and AS patients treated with biological drugs.

Methods: This cross-sectional study included all eligible patients referred to Imam Khomeini Hospital, Urmia, Iran from March 2021 to February 2022 and were randomly divided into two groups (anti-TNF group treated with methotrexate, rituximab, etanercept, adalimumab, infliximab and control group treated with methotrexate). Electrocardiogram (ECG) was performed on all participants at baseline and 6 months after initiation of treatment, and the QT, QTd, and TpTe were calculated with standard procedures.

Result: Of 128 patients with RA or AS, 64 patients were included in the anti-TNF group and control group, separately. There was predominance of male gender: 69 (53.9%) vs. 59 (46.1%) among all patients with mean age of 47.77 years. After 6 months (T6), the anti-TNF group already displayed a longer mean QT, QTc, and TpTe interval than control group (418.7 ± 15.6 ms vs. 414.0 ± 17.5 ms; $p = 0.03$; 461.7 ± 25.0 vs. 448.3 ± 11.2 , $p = 0.2$; 71.4 ± 6.7 vs. 70.4 ± 7.4 , $p = 0.6$, respectively). Post treatment increases in the QT were detected exclusively in the subgroup of patients being treated with Infliximab, Etanercept, Adalimumab, Rituximab for RA, which all were significant ($P = 0.002, 0.001, 0.001, 0.001$, respectively). In contrast, post treatment changes in the QTc and TpTe indices were not outstanding and statistically significant.

Conclusion: This study demonstrated that anti-TNF drugs induce a substantial increase in QT and QTc levels, which can cause considerable risks to patients due to their asymptomatic presentation. Unlike anti-TNF drugs, methotrexate does not cause significant changes in these parameters.

Introduction

Tumor necrosis factor alpha (TNF- α) is a versatile cytokine that exerts diverse effects on numerous cell types [1].

It is widely recognized as a key orchestrator of inflammatory responses and plays a pivotal role in the development of various inflammatory and autoimmune disorders [2]. The



presence of elevated levels of inflammatory cytokines in patients with congestive heart failure (CHF) was initially documented in 1990 [3]. Therapeutic interventions targeting TNF- α , including infliximab, etanercept, and adalimumab, have demonstrated significant clinical benefits across a spectrum of autoimmune and non-autoimmune diseases [4]. This therapeutic strategy has been approved for the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in several countries [5].

RA is a prevalent systemic inflammatory disorder affecting around 0.5-1% of the population [6]. Notably, RA patients exhibit a substantially elevated risk of heart failure (HF) compared to individuals without RA, even when accounting for established cardiovascular risk factors and coronary artery disease (CAD) [7]. This finding highlights the profound contribution of RA-specific immune/inflammatory pathways to the increased HF risk [8]. Additionally, AS is a chronic multi-systemic inflammatory rheumatologic condition primarily affecting the axial skeleton [9]. AS patients are susceptible to various cardiovascular manifestations, including aortic insufficiency secondary to aortitis, conduction abnormalities, and left ventricular diastolic dysfunction abnormalities attributable to excessive myocardial fibrosis and arrhythmias [10].

Elevated inflammation and sympathetic activity can lead to ventricular depolarization and repolarization abnormalities in patients with RA and AS [11-12]. Surface electrocardiography (ECG) is commonly employed to assess the electrical stability of the heart muscle [13]. Consequently, ventricular arrhythmias can be identified on surface ECG by utilizing the QT interval and T wave as markers of ventricular repolarization [14]. Recent investigations have demonstrated that the Tp-e interval, defined as the duration between the peak and the termination of the T wave on an ECG, can be employed as an index of the overall (transmural, apico-basal, and global) dispersion of repolarization [15]. However, the Tp-e interval is susceptible to variations in body weight and heart rate [16]. Recently, a novel index, the Tp-e/QT ratio, has been proposed as a more precise measure of ventricular repolarization dispersion compared to QTd, QTc, and Tp-e intervals and is independent of heart rate fluctuations [17].

While ventricular repolarization has been previously assessed using T wave and QT interval measurements in patients with RA and AS [18, 19], the novel repolarization indices Tp-e interval and QTc ratio have not yet been

investigated in RA and AS patients. This study aimed to evaluate the changes in QTc and Tp-e in RA and AS patients treated with biological drugs (methotrexate, rituximab, etanercept, adalimumab, infliximab).

Materials and Methods

This cross-sectional study was conducted after approval by the ethics committee of Urmia University of Medical Sciences (Code: IR.UMSU.REC.1399.080) and informed consent was obtained from all participants. In this study, all eligible patients referred to Imam Khomeini Hospital, Urmia, Iran from March 2021 to February 2022 were selected and randomly divided into two groups. The first group (anti-TNF group) comprised consecutive patients who met the American College of Rheumatology (ACR) criteria for RA10 or the European Spondylarthropathy Study Group criteria11 for SpA, exhibited active disease, and were eligible for anti-TNF treatment with methotrexate, rituximab, etanercept, adalimumab, or infliximab. The second group (control group) consisted of patients with RA or SpA who fulfilled the ACR criteria for RA and the Spondylarthropathy Study Group criteria for SpA, had never received anti-TNF therapy, and were candidates for treatment with methotrexate (MTX) monotherapy. Exclusion criteria included the use of drugs known to prolong QT intervals, and/or ischemic heart disease, hypertension, valvulopathy, diabetes, or thyroid disease.

Individuals in the anti-TNF group received methotrexate (15 mg/week), rituximab (25 mg twice weekly), etanercept (25 mg twice weekly), adalimumab (25 mg twice weekly), or infliximab (5 mg/kg every 8 weeks). Those in the MTX group received 25 mg of methotrexate, one dose at baseline and a second dose two weeks later. This cycle was repeated after six months. Physical examinations, serum electrolyte studies, and standard 6-lead ECGs were performed in both groups at baseline (T0) and repeated in both groups six months after the initiation of treatment (T6).

Electrocardiography

The 6-lead ECG was recorded with a paper speed of 50 mm/s and amplitude of 10 mm/mV using a Nihon Kohden electrocardiograph (Tokyo, Japan), while the patient was resting in a supine position. Only artifact-free segments of the ECG were considered for analysis. Resting heart rate was

measured directly from the ECG. QT and TP-e intervals were measured manually by two cardiologists who were blinded to the patient data. To minimize measurement error, calipers and a magnifying glass were used to precisely determine the QT and TP-e intervals. Subjects with U waves on their ECGs were excluded from the study to ensure consistency in data interpretation. The average of three readings for each lead was calculated. The QT interval was measured from the onset of the QRS complex to the end of the T wave and was corrected for heart rate using the Bazett formula: $cQT = QTd$ (R-R interval).

The QTd was quantified as the difference between the longest and shortest QT intervals among the six ECG leads [20]. The normal limits for QTd are 460 ms for women and 450 ms for men, while the minimum limit is 390 ms for both genders. The tail method was utilized to determine TpTe. This approach entails drawing two perpendicular lines from the peak and offset of the T wave, where it intersects the isoelectric line. The horizontal distance between these lines represents the TpTe interval. For a smooth T wave, the perpendicular line is drawn at its midpoint; for a notched T wave, the midpoint of the notch serves as the reference point. The Tp-e interval was measured from the precordial leads [15]. The Tp-e/QT ratio was then calculated. The interobserver and intraobserver coefficients of variation were 3.2% and 2.7%, respectively. All measurements and calculations were overseen by a cardiologist and modified if required to guarantee the study's validity and reliability. All ECG recordings were performed using a single device, and all patients were positioned supine. To measure the intervals, the patients' ECG tapes were scanned, and the desired interval was precisely measured using MATLAB 2018 mathematical software by a qualified engineer.




Figure 1: Illustration of the Electrocardiogram

Sample sizing

Based on the following formula, and according to the study of DI FRANCO, et al. [21], according to the QT value (intervention group: 2.416 ± 31.9 and control group: 1.400 ± 28.4) and taking into account the confidence interval of 90% and the power of 80%, 64 people were determined in each group.

$$n = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_1(1 - P_1) + P_2(1 - P_2)]}{(P_1 - P_2)^2}$$

Statistical analysis

All analyses were performed with the Statistical Package for Social Sciences 21 (SPSS, Chicago, IL, USA). The results obtained for qualitative data are reported as percentage and frequency and quantitative data as Mean \pm SD. T-test was used to compare 2 means and ANOVA test was used to compare more than two means. In case of non-normality of data distribution, non-parametric test equivalents were used. Normality of data distribution was tested using Kolmogorov-Smirnov test. A significance level of less than 0.05 was considered.

Results

Of 128 patients with RA or AS, 64 patients were included in the anti-TNF group and control group, separately. According to Figure 2, there was predominance of male gender: 69 (53.9%) vs. 59 (46.1%) among all patients. In the anti-TNF group, 55.6% (35 people) were men and 44.4% (28 people) were women, and in the control group 51.6% (33 people) were men and 48.4% (31 people) were women. No difference was found respect to gender difference ($P=0.65$). The mean age of all patients was 47.77 years. In the anti-TNF group it was 48.33 ± 6.65 years old and it was 47.25 ± 8.39 years old in the control group, which was not significant ($P=0.42$) Figure 3.




Figure 2: Sexual distribution of the studied patients in two groups




Figure 3: Age distribution of studied patients

According to Table 1, at baseline (T0), the anti-TNF group already displayed a significantly shorter mean QT than control group (405.4 ± 10.2 ms vs. 407.1 ± 9.1 ms, $p = 0.4$). Moreover, it longer mean QTc and TpTe than control group

(446.5 ± 14.9 vs. 454.6 ± 17.4 , $p = 0.2$ and 70.7 ± 7.7 vs. 69.8 ± 8.7 , $p = 0.2$, respectively).

After 6 months (T6), the anti-TNF group already displayed a longer mean QT, QTc, and TpTe interval than control group (418.7 ± 15.6 ms vs. 414.0 ± 17.5 ms; $p = 0.03$; 461.7 ± 25.0 vs. 448.3 ± 11.2 , $p = 0.2$; 71.4 ± 6.7 vs. 70.4 ± 7.4 , $p = 0.6$, respectively) (Table 1).

Table 1: ECG indices at baseline (T0) and after 6 months of treatment (T6) between TNF and control groups. Data are given in milliseconds.

	Anti TNF	Control group		Anti TNF	Control group	
Variables	T0		P-value	T6		P-value
QT	405.4±10.2	407.1±9.1	0.4	418.7±15.6	414.0±17.5	0.03
QTc	446.5±14.9	454.6±17.4	0.02	461.7±25.0	448.3±11.2	0.01
TpTe	70.7±7.7	69.8±8.7	0.2	71.4±6.7	70.4±7.4	0.48

Table 2 shows the ECG indices before and after treatment intra groups separately. At T6, there were significant increases over baseline values in the QT, QTC ($P<0.001$ and $P=0.02$), But in TpTe examination, although its amount increased after treatment, statistically significant change was

not observed ($P=0.2$). In patients treated with MTX, the mean QT, QTc and TpTe were increased 6 months after the treatment, but no significant difference was observed in any of the investigated criteria before and after treatment ($P=0.08$, $P=0.09$ and $P=0.2$).

Table 2: ECG indices at baseline (T0) and after 6 months of treatment (T6) intra group TNF and control groups. Data are given in milliseconds.

	Anti TNF			Control group		
Variables	T0	T6	P-value	T0	T6	P-value
QT	405.4±10.2	418.7±15.6	<0.001	407.1±9.1	414.0±17.5	0.08
QTc	446.5±14.9	448.3±11.2	0.02	454.6±17.4	461.7±25.0	0.09
TpTe	70.7±7.7	71.4±6.7	0.2	69.8±8.7	70.4±7.4	0.2

Table 3 shows the results of subgroup analysis of QT indices in the anti-TNF group. Post treatment increases in the QT were detected exclusively in the subgroup of patients being treated with Infliximab, Etanercept, Adalimumab, Rituximab

for RA, which all were significant ($P=0.002$, 0.001 , 0.001 , 0.001 , respectively). In contrast, post treatment changes in the QTc and TpTe indices were not outstanding and statistically significant.

Table 3: Subgroup analysis of QT indices changes in the anti-TNF group

Anti-TNF drugs

	Infliximab			Etanercept			Adalimumab			Rituximab		
	T0	T6	P	T0	T6	P	T0	T6	P	T0	T6	P
QT	404.5±10.7	421.0±15.6	0.02	404.7±10.9	414.25±3.4	0.01	406.9±13.1	420.5±21.8	0.01	405.6±6.2	419.1±10.9	0.01
QTc	447.5±5.7	448.5±12.9	0.3	445.2±10.3	447.5±6.7	0.1	449.6±19.4	449.8±15.9	0.9	444.0±13.8	447.5±7.9	0.08
TpTe	71.2±8.5	71.7±6.3	0.6	66.2±5.8	68.7±6.1	0.1	72.5±6.7	72.8±7.1	0.7	72.7±8.1	72.5±7.0	0.8

Discussion

Cardiac conduction abnormalities and arrhythmias are significantly more prevalent in RA and AS patients compared to the general population, likely attributed to the increased presence of inflammatory cells, chemokines, and cytokines, myocardial damage, and fibrosis [22]. Individuals with cardiac disorders have been shown to exhibit elevated serum levels of TNF- α compared to healthy counterparts [23]. Moreover, studies have indicated that the myocardium itself can generate TNF- α , but the underlying mechanism of TNF- α -induced cardiac injury remains unclear [24]. Our study investigated the impact of anti-TNF agents on cardiac conduction and arrhythmias in RA and SpA patients without prior CVD. Sure, here is an academically accurate paraphrase of the provided text:

This study demonstrated that patients receiving anti-TNF therapy exhibited significant post-treatment increases in the QT, QTc, and TpTe intervals, but these changes did not exceed normal limits, were not associated with any clinical manifestations of cardiovascular disease (CVD), and were independent of the underlying disease (RA vs SpA) or the specific TNF antagonist used. CVD is a well-established extra-articular complication of RA and other inflammatory rheumatic diseases [25]. It is typically attributed to premature atherosclerosis development, and several studies have revealed elevated cardiovascular mortality in patients with these disorders [26]. Investigations have found notable QTc prolongation in RA patients compared to healthy controls [27], and also in patients with SpA during the early stages of the disease [28].

Our study revealed that after six months of treatment, QT and QTc values significantly increased in patients receiving anti-TNF agents, while TpTe values showed an increment post-treatment but failed to reach statistical significance. No such changes were observed in the MTX group. Pathological prolongation of QT interval and QTc is strongly associated with ventricular arrhythmias and sudden death. DI Franco et al. [21] similarly reported asymptotically elevated QT intervals and dispersion in patients with inflammatory polyarthritis treated with anti-TNF- α drugs. Abnormalities of ventricular repolarization due to cardiac structural alterations, autonomic dysfunction, and increased inflammatory activity could contribute to increased sudden cardiac deaths and ventricular arrhythmias in RA patients

[29]. QTc and TpTe intervals were significantly longer in RA and AS patients compared to the control group, suggesting that increased cardiovascular morbidity and mortality may arise from complex ventricular arrhythmias in these patients [30]. Additionally, Janse van Rensburg et al. [31] reported that impaired autonomic nervous system function could play a crucial role in the development of ventricular arrhythmias in RA and AS.

The Tp-e interval and Tp-e/QT ratio are widely recognized electrocardiographic markers of heightened ventricular repolarization dispersion [32]. These markers are also employed as electrocardiographic indices of ventricular arrhythmogenesis and sudden cardiac death [33]. Prior investigations have demonstrated that prolongation of the Tp-e interval is linked to increased mortality in Brugada syndrome, long QT syndromes, hypertrophic cardiomyopathy, and patients undergoing primary percutaneous coronary intervention for myocardial infarction [34, 35]. Several researchers have examined repolarization patterns in RA patients, observing that QTc is extended compared to controls [29, 36]. However, in these studies, solely QTc was utilized to evaluate the homogeneity of cardiac repolarization, and no information about the association with inflammation was presented. Our study revealed that the Tp-e interval and Tp-e/QT ratio were elevated in RA and AS patients, and these ventricular repolarization indices were correlated with inflammation [37]. Myocardial fibrosis is a recognized complication of RA, thought to arise due to chronic inflammation [38]. Hence, the involvement of myocardial tissue may induce the development of heterogeneity in repolarization, potentially contributing to the emergence of ventricular arrhythmias in RA patients.

Limitations

The primary limitation of our study lies in its cross-sectional design and the absence of patient follow-up. We failed to evaluate the connection between ventricular arrhythmias and Tp-e interval and Tp-e/QT ratio. Additionally, the study population could not be prospectively monitored for ventricular arrhythmic episodes. As a result, we were unable to assess the potential prognostic significance of the electrocardiographic ventricular repolarization indices concerning future adverse events. Long-term follow-up and

large-scale prospective studies are, therefore, required to determine the predictive value of prolonged Tp-e interval and increased Tp-e/QT ratio in this population. Furthermore, manual measurement of QT and Tp-e intervals on paper-printed electrocardiograms might have weakened the study outcomes as more reliable measurements could be obtained using a high-resolution digital system.

Conclusion

This study demonstrated that Tp-e interval and Tp-e/QT ratio were elevated in RA and AS patients. As previously reported, anti-TNF drugs induce a substantial rise in QT and QTc levels, which can pose considerable risks to patients due to their asymptomatic presentation. In contrast to anti-TNF drugs, our study revealed that MTX does not produce significant alterations in these parameters. Consequently, it can be considered a safer treatment option for RA and AS patients.

Statements and Declarations

Funding support

The authors did not receive support from any organization for the submitted work

Competing interests

The authors have no competing interests to declare that are relevant to the content of this article.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Urmia University of Medical sciences (No. IR.UMSU.REC.1399.080).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Author contributions

M A A: Conceptualization, the original draft writing, investigation, writing including reviewing and editing and investigation and formal analysis; M H P: Conceptualization, supervision, and project administration; T M: Conceptualization, the original draft writing, investigation

Acknowledgments

The authors would like to express their gratitude to the clinical research development unit of Imam Khomeini

Hospital, Urmia University of Medical Sciences, for English editing solid tumor research center.

References

1. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF- α) in autoimmune disease and current TNF- α inhibitors in therapeutics. *International journal of molecular sciences*. 2021 Mar 8;22(5):2719. doi: [10.3390/ijms22052719](https://doi.org/10.3390/ijms22052719).
2. Van Loo G, Bertrand MJ. Death by TNF: a road to inflammation. *Nature Reviews Immunology*. 2023 May;23(5):289-303. doi.org/10.1038/s41577-022-00792-3
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl J Med*. 1990; 323:236–241. doi: [10.1056/NEJM199007263230405](https://doi.org/10.1056/NEJM199007263230405).
4. Andretto V, Dusi S, Zilio S, Repellin M, Kryza D, Ugel S, Lollo G. Tackling TNF- α in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA-based nanomedicines. *Advanced Drug Delivery Reviews*. 2023 Sep 1;115080. doi.org/10.1016/j.addr.2023.115080
5. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Favalli EG, Becciolini A, Biggioggero M, Benucci M, Gobbi FL, Grossi V. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. *In Seminars in Arthritis and Rheumatism* 2016 Apr 1 (Vol. 45, No. 5, pp. 519-532). WB Saunders. doi.org/10.1016/j.semarthrit.2015.10.001
6. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. *Rheumatology international*. 2017 Sep;37:1551-7. doi: [10.1007/s00296-017-3726-1](https://doi.org/10.1007/s00296-017-3726-1). Epub 2017 Apr 28.
7. Lee TH, Song GG, Choi SJ, Seok H, Jung JH. Relationship of rheumatoid arthritis and coronary

- artery disease in the Korean population: a nationwide cross-sectional study. *Advances in Rheumatology*. 2019 Sep 9;59. doi: 10.1186/s42358-019-0084-6
8. Park E, Griffin J, Bathon JM. Myocardial dysfunction and heart failure in rheumatoid arthritis. *Arthritis & Rheumatology*. 2022 Feb;74(2):184-99. doi: 10.1002/art.41979
9. Wenker KJ, Quint JM. Ankylosing Spondylitis. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK47017/>
10. Aksoy H, Okutucu SE, Sayin BY, Ercan EA, Kaya EB, Ozdemir O, Inanici F, Aytemir K, Oto A. Assessment of cardiac arrhythmias in patients with ankylosing spondylitis by signal-averaged P wave duration and P wave dispersion. *European Review for Medical & Pharmacological Sciences*. 2016 Mar 15;20(6). PMID: 27049266.
11. Adlan AM. Inflammation and Heart Rate-corrected QT Interval: Evidence for a Potentially Reversible Cause of Sudden Death in Patients with Rheumatoid Arthritis?. *The Journal of Rheumatology*. 2018 Dec 1;45(12):1609-10. doi: <https://doi.org/10.3899/jrheum.180921>
12. Lazzerini PE, Abbate A, Boutjdir M, Capecci PL. Firing the rhythm: inflammatory cytokines and cardiac arrhythmias. *JACC: Basic to Translational Science*. 2023 Feb 15. doi: <https://doi.org/10.1016/j.jacbts.2022.12.004>
13. Xie L, Li Z, Zhou Y, He Y, Zhu J. Computational Diagnostic Techniques for Electrocardiogram Signal Analysis. *Sensors (Basel)*. 2020 Nov 5;20(21):6318. doi: 10.3390/s20216318.
14. Monitillo F, Leone M, Rizzo C, Passantino A, Iacoviello M. Ventricular repolarization measures for arrhythmic risk stratification. *World J Cardiol*. 2016 Jan 26;8(1):57-73. doi: 10.4330/wjc.v8.i1.57.
15. Akboğa MK, Gülcihan Balcı K, Yılmaz S, Aydın S, Yayla Ç, Ertem AG, Ünal S, Balcı MM, Balbay Y, Aras D, Topaloğlu S. Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. *Anatol J Cardiol*. 2017 Jul;18(1):48-53. doi: 10.14744/AnatolJCardiol.2017.7581.
16. Kahraman S, Dogan A, Demirci G, Guler A, Kalkan AK, Uzun F, Kurtoglu N, Erturk M, Kalkan ME. The association between Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios and coronary artery disease spectrum and syntax score. *International Journal of Cardiovascular Sciences*. 2021 Jan 22;34:179-87. doi: <https://doi.org/10.36660/ijcs.20190149>
17. Zhao X, Xie Z, Chu Y, Yang L, Xu W, Yang X, et al. Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *Clin Cardiol*. 2012; 35: 559 - 64. doi: 10.1002/clc.22022
18. Zehir R, Karabay CY, Kalaycı A, Akgün T, Kılıçgedik A, Kırmacı C. Evaluation of Tpe interval and Tpe/QT ratio in patients with slow coronary flow. *Anatol J Cardiol*. 2015 Jun;15(6):463-7. doi: 10.5152/akd.2014.5503
19. Yenerçay M, Arslan U, Doğduş M, Günel Ö, Öztürk ÇE, Aksan G, Erdoğan G, Gül S, Yontar OC, Şen A. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. *Journal of Electrocardiology*. 2020 Sep 1;62:5-9. doi: 10.1016/j.jelectrocard.2020.07.005.
20. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. *Br Heart J*. 1990 Jun;63(6):342-4. doi: 10.1136/hrt.63.6.342.
21. Di Franco M, Paradiso M, Ceccarelli F, Scrivo R, Spinelli FR, Iannuccelli C, Valesini G. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion. *J Rheumatol*. 2012 Jan;39(1):41-5. doi: 10.3899/jrheum.110158.
22. Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. *BioMed research international*. 2014 Jan 1;2014. <https://doi.org/10.1155/2014/367359>

23. Noori NM, Moghaddam MN, Teimouri A, Shahramian I, Keyvani B. Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease. *Niger Med J*. 2016 Jul-Aug;57(4):233-7. doi: [10.4103/0300-1652.188353](https://doi.org/10.4103/0300-1652.188353).
24. Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. *Lupus* 2005;14:780-4. doi: [10.1191/0961203305lu2220aa](https://doi.org/10.1191/0961203305lu2220aa).
25. Rawla P. Cardiac and vascular complications in rheumatoid arthritis. *Reumatologia*. 2019;57(1):27-36. doi: [10.5114/reum.2019.83236](https://doi.org/10.5114/reum.2019.83236).
26. Legge A, Hanly JG. Managing premature atherosclerosis in patients with chronic inflammatory diseases. *CMAJ*. 2018 Apr 9;190(14):E430-E439. doi: [10.1503/cmaj.170776](https://doi.org/10.1503/cmaj.170776).
27. Chauhan K, Ackerman MJ, Crowson CS, Matteson EL, Gabriel SE. Population-based study of QT interval prolongation in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1):84-9. Epub 2015 Jan 8. PMID: [25572282](https://pubmed.ncbi.nlm.nih.gov/25572282/); PMCID: [PMC4366055](https://pubmed.ncbi.nlm.nih.gov/PMC4366055/).
28. Acar G, Yorgun H, Inci MF, Akkoyun M, Bakan B, Nacar AB, Dirnak I, Cetin GY, Bozoglan O. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with ankylosing spondylitis. *Mod Rheumatol*. 2013 Apr 12. doi: [10.1007/s10165-013-0881-4](https://doi.org/10.1007/s10165-013-0881-4).
29. Masoud S, Lim PB, Kitas GD, Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. *World J Cardiol*. 2017 Jul 26;9(7):562-573. doi: [10.4330/wjc.v9.i7.562](https://doi.org/10.4330/wjc.v9.i7.562).
30. Hayward RM, Tseng ZH. Arrhythmias in Complex Congenital Heart Disease. *Card Electrophysiol Clin*. 2014 Sep 1;6(3):623-634. doi: [10.1016/j.ccep.2014.05.014](https://doi.org/10.1016/j.ccep.2014.05.014).
31. Janse van Rensburg DC, Ker JA, Grant CC, Fletcher L. Autonomic impairment in rheumatoid arthritis. *Int J Rheum Dis*. 2012 Aug;15(4):419-26. doi: [10.1111/j.1756-185X.2012.01730.x](https://doi.org/10.1111/j.1756-185X.2012.01730.x).
32. Gürdal A, Eroğlu H, Helvacı F, Sümerkan MÇ, Kasalı K, Çetin Ş, Aksan G, Kiliçkesmez K. Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with subclinical hypothyroidism. *Ther Adv Endocrinol Metab*. 2017 Mar;8(3):25-32. doi: [10.1177/2042018816684423](https://doi.org/10.1177/2042018816684423).
33. Ajibare AO, Olabode OP, Fagbemi EY, Akinlade OM, Akintunde AA, Akinpelu OO, Olatunji LA, Soladoye AO, Opadijo OG. Assessment of Ventricular Repolarization in Sickle Cell Anemia Patients: The Role of QTc Interval, Tp-e Interval and Tp-e/QTc Ratio and Its Gender Implication. *Vasc Health Risk Manag*. 2020 Dec 7;16:525-533. doi: [10.2147/VHRM.S259766](https://doi.org/10.2147/VHRM.S259766).
34. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J, Chugh SS. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. *Circ Arrhythm Electrophysiol*. 2011 Aug;4(4):441-7. doi: [10.1161/CIRCEP.110.960658](https://doi.org/10.1161/CIRCEP.110.960658).
35. Saour BM, Wang JH, Lavelle MP, Mathew RO, Sidhu MS, Boden WE, Sacco JD, Costanzo EJ, Hossain MA, Vachharanji T, Alrefae A, Asif A. TpTe and TpTe/QT: novel markers to predict sudden cardiac death in ESRD? *J Bras Nefrol*. 2019 Jan-Mar;41(1):38-47. doi: [10.1590/2175-8239-JBN-2017-0021](https://doi.org/10.1590/2175-8239-JBN-2017-0021).
36. Niemeijer MN, van den Berg ME, Eijgelsheim M, van Herpen G, Stricker BH, Kors JA, Rijnbeek PR. Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review. *Heart*. 2014 Dec;100(23):1831-6. doi: [10.1136/heartjnl-2014-305671](https://doi.org/10.1136/heartjnl-2014-305671).
37. Çetin GY, Yıldırım MN, Zencir C, Karaman K, Çetin M, Sayarlıoğlu M. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with rheumatoid arthritis. *Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol* 2014;42(1):29-34 doi: [10.5543/tkda.2014.52959](https://doi.org/10.5543/tkda.2014.52959)
38. Ntusi NAB, Piechnik SK, Francis JM, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping. *JACC Cardiovasc Imaging*. 2015 May;8(5):526-536. doi: [10.1016/j.jcmg.2014.12.025](https://doi.org/10.1016/j.jcmg.2014.12.025).